Loading
A phase 3 trial of aumolertinib, pemetrexed and cisplatin in lung cancer, run by Chinese Academy of Medical Sciences, now recruiting.
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection is a phase 3, randomised interventional study registered as NCT04762459 by Chinese Academy of Medical Sciences, with a registry enrolment figure of 606 participants, started 2021-08-01 and due to reach its primary completion in 2026-05. Interventions recorded: Almonertinib; Pemetrexed; Cisplatin. Conditions listed: Non-small Cell Lung Carcinoma. Primary outcome: Disease free survival (DFS). Lung eligibility wording from the registry: "Histologically confirmed diagnosis of primary non small lung cancer (NSCLC) on predominantly non-squamous histology". Sites: China. No results are recorded here; the registry entry is the source.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Cisplatin and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Cisplatin and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Cisplatin and the tag lung-deep-dive.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Cisplatin and the tag lung-deep-dive.